|
1
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garfield SS, Gavaghan MB, Armstrong SO and
Jones JS: The cost-effectiveness of blue light cystoscopy in
bladder cancer detection: United States projections based on
clinical data showing 4.5 years of follow up after a single
hexaminolevulinate hydrochloride instillation. Can J Urol.
20:6682–6689. 2013.PubMed/NCBI
|
|
3
|
Sullivan PS, Chan JB, Levin MR and Rao J:
Urine cytology and adjunct markers for detection and surveillance
of bladder cancer. Am J Transl Res. 2:412–440. 2010.PubMed/NCBI
|
|
4
|
Talwar R, Sinha T, Karan SC, Doddamani D,
Sandhu A, Sethi GS, Srivastava A, Narang V, Agarwal A and Adhlakha
N: Voided urinary cytology in bladder cancer: is it time to review
the indications? Urology. 70:267–271. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wiener HG: Cytology of the urinary tract.
A modern investigation method? Pathologe. 28:354–359. 2007.(In
German). PubMed/NCBI
|
|
6
|
Fradet Y and Lockhard C: Performance
characteristics of a new monoclonal antibody test for bladder
cancer: ImmunoCyt trade mark. Can J Urol. 4:400–405.
1997.PubMed/NCBI
|
|
7
|
Têtu B, Tiguert R, Harel F and Fradet Y:
ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in
patients followed for urothelial carcinoma. Mod Pathol. 18:83–89.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Messing EM, Teot L, Korman H, Underhill E,
Barker E, Stork B, Qian J and Bostwick DG: Performance of urine
test in patients monitored for recurrence of bladder cancer: a
multicenter study in the United States. J Urol. 174:1238–1241.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mian C, Maier K, Comploj E, Lodde M,
Berner L, Lusuardi L, Palermo S, Vittadello F and Pycha A:
uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma:
an update on 1991 analyses. Cancer. 108:60–65. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lodde M, Mian C, Comploj E, Palermo S,
Longhi E, Marberger M and Pycha A: uCyt+ test: alternative to
cystoscopy for less-invasive follow-up of patients with low risk of
urothelial carcinoma. Urology. 67:950–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sullivan PS, Nooraie F, Sanchez H,
Hirschowitz S, Levin M, Rao PN and Rao J: Comparison of ImmunoCyt,
UroVysion, and urine cytology in detection of recurrent urothelial
carcinoma: a ‘split-sample’ study. Cancer. 117:167–173.
2009.PubMed/NCBI
|
|
12
|
Higgins JP, Thompson SG, Deeks JJ and
Altman DG: Measuring inconsistency in meta-analyses. BMJ.
327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
14
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
DerSimonian R and Kacker R: Random-effects
model for meta-analysis of clinical trials: an update. Contemp Clin
Trials. 28:105–114. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walter SD: Properties of the summary
receiver operating characteristic (SROC) curve for diagnostic test
data. Stat Med. 21:1237–1256. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Altman DG and Bland JM: Diagnostic tests
3: receiver operating characteristic plots. BMJ. 309:1881994.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yafi FA, Brimo F, Steinberg J, Aprikian
AG, Tanguay S and Kassouf W: Prospective analysis of sensitivity
and specificity of urinary cytology and other urinary biomarkers
for bladder cancer. Urol Oncol. 33:66.e25–66.e31. 2015. View Article : Google Scholar
|
|
19
|
Soyuer I, Sofikerim M, Tokat F, Soyuer S
and Ozturk F: Which urine marker test provides more diagnostic
value in conjunction with standard cytology- ImmunoCyt/uCyt+ or
Cytokeratin 20 expression. Diagn Pathol. 4:202009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Horstmann M, Patschan O, Hennenlotter J,
Senger E, Feil G and Stenzl A: Combinations of urine-based tumour
markers in bladder cancer surveillance. Scand J Urol Nephrol.
43:461–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Toma MI, Friedrich MG, Hautmann SH, Jäkel
KT, Erbersdobler A, Hellstern A and Huland H: Comparison of the
ImmunoCyt test and urinary cytology with other urine tests in the
detection and surveillance of bladder cancer. World J Urol.
22:145–149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hautmann S, Toma M, Lorenzo Gomez MF,
Friedrich MG, Jaekel T, Michl U, Schroeder GL, Huland H, Juenemann
KP and Lokeshwar VB: Immunocyt and the HA-HAase urine tests for the
detection of bladder cancer: a side-by-side comparison. Eur Urol.
46:466–471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis
CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC and Lijmer
JG: Standards for Reporting of Diagnostic Accuracy: The STARD
statement for reporting studies of diagnostic accuracy: explanation
and elaboration. Clin Chem. 49:7–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis
CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D and de Vet
HC: STARD Group: Towards complete and accurate reporting of studies
of diagnostic accuracy: the STARD initiative. Fam Pract. 21:4–10.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raab SS, Grzybicki DM, Vrbin CM and
Geisinger KR: Urine cytology discrepancies: frequency, causes, and
outcomes. Am J Clin Pathol. 127:946–953. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deshpande V and McKee GT: Analysis of
atypical urine cytology in a tertiary care center. Cancer.
105:468–475. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mokhtar GA, Al-Dousari M and Al-Ghamedi D:
Diagnostic significance of atypical category in the voided urine
samples: a retrospective study in a tertiary care center. Urol Ann.
2:100–106. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kapur U, Venkataraman G and Wojcik EM:
Diagnostic significance of ‘atypia’ in instrumented versus voided
urine specimens. Cancer. 114:270–274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Odisho AY, Berry AB, Ahmad AE, Cooperberg
MR, Carroll PR and Konety BR: Reflex ImmunoCyt testing for the
diagnosis of bladder cancer in patients with atypical urine
cytology. Eur Urol. 63:936–940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vriesema JL, Atsma F, Kiemeney LA, Peelen
WP, Witjes JA and Schalken JA: Diagnostic efficacy of the ImmunoCyt
test to detect superficial bladder cancer recurrence. Urology.
58:367–371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmitz-Dräger BJ, Beiche B, Tirsar LA,
Schmitz-Dräger C, Bismarck E and Ebert T: Immunocytology in the
assessment of patients with asymptomatic microhaematuria. Eur Urol.
51:1582–1588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mian C, Lodde M, Comploj E, Palermo S,
Mian M, Maier K and Pycha A: The value of the ImmunoCyt/uCyt+ test
in the detection and follow-up of carcinoma in situ of the urinary
bladder. Anticancer Res. 25:3641–3644. 2005.PubMed/NCBI
|
|
33
|
Moreno SG, Sutton AJ, Thompson JR, Ades
AE, Abrams KR and Cooper NJ: A generalized weighting
regression-derived meta-analysis estimator robust to small-study
effects and heterogeneity. Stat Med. 31:1407–1417. 2012. View Article : Google Scholar : PubMed/NCBI
|
